Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

4.0%

1 terminated out of 25 trials

Success Rate

93.3%

+6.8% vs benchmark

Late-Stage Pipeline

32%

8 trials in Phase 3/4

Results Transparency

71%

10 of 14 completed with results

Key Signals

10 with results93% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (4)
P 1 (3)
P 2 (4)
P 3 (7)
P 4 (1)

Trial Status

Completed14
Unknown9
Terminated1
Not Yet Recruiting1

Trial Success Rate

93.3%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT04950764Phase 1Completed

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT07082751Not Yet Recruiting

Prognostic Model for MASLD Related Cirrhosis

NCT06525311Phase 1Completed

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

NCT04210245Phase 2CompletedPrimary

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

NCT05485714Completed

Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis

NCT06147518Not ApplicableUnknownPrimary

To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

NCT03439254Phase 3CompletedPrimary

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT04060147Phase 1Terminated

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

NCT03144700UnknownPrimary

The Natural History and Prognostic Factors of Compensated Cirrhosis.

NCT05357599Not ApplicableUnknown

The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis

NCT05367596Not ApplicableCompleted

OPTIMIzing muScle Preservation in paTients wIth Cirrhosis

NCT03656068Phase 2Completed

An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

NCT03990753UnknownPrimary

Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901)

NCT02642432Phase 3Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

NCT01995071Phase 2Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

NCT01704755Phase 3Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

NCT02219503Phase 3Completed

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

NCT03749954UnknownPrimary

Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Cirrhosis

NCT03037151Phase 4UnknownPrimary

Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV

NCT04196998Not ApplicableUnknown

Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis

Scroll to load more

Research Network

Activity Timeline